An interventional study of Ultrasound-guided glenohumeral space isolated corticosteroid injection and Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection in Adhesive Capsulitis and Adhesive Capsulitis of Shoulder, sponsored by Chuncheon Sacred Heart Hospital. Completed at 1 site in South Korea. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Chuncheon Sacred Heart Hospital · Not applicable, Interventional, and Treatment
This clinical trial investigates whether concomitant capsule-preserving hydrodilatation (CSHD) is more effective than isolated glenohumeral corticosteroid injection (CS) in treating shoulder adhesive capsulitis. The main questions it aims to answer are
Group CS will receive an ultrasound-guided glenohumeral corticosteroid injection only, with a solution of 5 mL.
Group CSHD will receive an ultrasound-guided glenohumeral corticosteroid with hydrodilatation, with a solution of 20 mL.
Clinical scores and range of motion will be compared between the groups up to six months post-injection.
A single-centre, double-blinded, prospective randomised controlled trial involving patients diagnosed with adhesive capsulitis of the shoulder (AC).
Patients were randomly allocated to either corticosteroid injection with hydrodilatation (group CSHD) or corticosteroid injection only (group CS).
For the CS group, a solution of 1 mL triamcinolone (40mg) and 4 mL 1% lidocaine, 5 mL in total, was injected intraarticularly through the posterior approach using ultrasound guidance.
The CSHD group received an injection of 20 mL with 15 mL of normal saline added to the abovementioned 5 mL solution. The dilatation of the joint capsule was confirmed by the increase in distance between the capsule and the humeral head.
Patients underwent the following assessments just before the injection, and at post-injection three weeks, seven weeks, three months, and six months.
Range of motion in forward elevation, external rotation, and internal rotation Clinical scores include the pain visual analogue scale (pVAS), the American Shoulder and Elbow Surgeons score, and the Constant-Murley score.
Subjective patient satisfaction was recorded on a scale from 0 to 100, with 100 being the most satisfied.
The recorded data were compared within each group before and after the injection, and also between the groups.
411 studies on the registry are indexed under Bursitis; 112 are open to participants now.
This study's enrollment of 50 is above the median of 45 across 371 interventional studies indexed under Bursitis.
Browse Bursitis studies →Chuncheon Sacred Heart Hospital is the lead sponsor of 55 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Two or more of the following criteria within the shoulder's range of motion:
Exclusion Criteria:
Ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine.
Procedure: Ultrasound-guided glenohumeral space isolated corticosteroid injection · Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution · Drug: 4mL of Lidocaine 1% Solution Injectable Solution
Ultrasound-guided posterior approach of glenohumeral space hydrodilatation for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, and 15 mL normal saline
Procedure: Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection · Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution · Drug: 4mL of Lidocaine 1% Solution Injectable Solution · Drug: 15mL of Normal Saline
Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
American Shoulder and Elbow Surgeons (ASES) shoulder score
Patient-reported shoulder satisfaction score, 0-100, higher scores mean a better outcome.
Time frame: Change from the baseline to 7 weeks
Range of motion (ROM)
ROM in degrees, forward elevation (0-150), external rotation (0-90), and internal rotation (0-90)
Time frame: Change from the baseline to 6 months
Visual analog scale (VAS) for pain
Patient-reported 0-10 scale of pain, 0: no pain, 10: very severe pain
Time frame: Change from the baseline to 6 months
Constant-Murley score
Patient-reported and healthcare provider-assessed shoulder satisfaction score, 0-100, higher scores mean a better outcome.
Time frame: Change from the baseline to 6 months
Plan to share: No
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chuncheon Sacred Heart Hospital